BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 12185293)

  • 1. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
    Malet-Martino M; Martino R
    Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prodrugs of 5-fluorouracil.
    Malet-Martino M; Jolimaitre P; Martino R
    Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):267-310. PubMed ID: 12678747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
    Di Costanzo F; Sdrobolini A; Gasperoni S
    Crit Rev Oncol Hematol; 2000 Aug; 35(2):101-8. PubMed ID: 10936467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uracil-tegafur in gastric carcinoma: a comprehensive review.
    Takiuchi H; Ajani JA
    J Clin Oncol; 1998 Aug; 16(8):2877-85. PubMed ID: 9704742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oral fluorouracil prodrugs.
    Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral chemotherapy agents.
    Royce ME; Hoff PM; Pazdur R
    Curr Oncol Rep; 2000 Jan; 2(1):31-7. PubMed ID: 11122822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 5-FU analogues in the treatment of breast cancer.
    Bunnell CA; Winer EP
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):39-43. PubMed ID: 9830624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine: a novel agent for the treatment of solid tumors.
    Johnston PG; Kaye S
    Anticancer Drugs; 2001 Sep; 12(8):639-46. PubMed ID: 11604550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
    Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.